A5056723731- Childhood Cancer Survivors' Quality of Life
- Acute Lymphoblastic Leukemia research
- Adolescent and Pediatric Healthcare
- Palliative Care and End-of-Life Issues
- HER2/EGFR in Cancer Research
- Pharmaceutical studies and practices
- Cancer Treatment and Pharmacology
- Reproductive Health and Technologies
- Chronic Disease Management Strategies
- Chronic Kidney Disease and Diabetes
- Cancer and Skin Lesions
- Chemotherapy-induced cardiotoxicity and mitigation
- Healthcare Systems and Practices
- Neuroblastoma Research and Treatments
- Assisted Reproductive Technology and Twin Pregnancy
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- Radiation Dose and Imaging
- Health Systems, Economic Evaluations, Quality of Life
- Reproductive Biology and Fertility
- Monoclonal and Polyclonal Antibodies Research
- Chemotherapy-induced organ toxicity mitigation
- Family Support in Illness
- Cardiovascular Function and Risk Factors
- Hedgehog Signaling Pathway Studies
Agence Nationale de Sécurité du Médicament et des Produits de Santé
2021-2024
Agence de la Biomédecine
2024
l'Assurance Maladie
2024
Conservatoire National des Arts et Métiers
2022-2024
National Health Insurance Service
2024
Inserm
2018-2023
Centre de recherche en Epidémiologie et Santé des Populations
2018-2023
Université de Versailles Saint-Quentin-en-Yvelines
2018-2023
Université Paris-Saclay
2018-2023
Université Paris-Sud
2020-2023
Abstract STUDY QUESTION What are the data and trends on ART IUI cycle numbers their outcomes, fertility preservation (FP) interventions, reported in 2019 as compared to previous years? SUMMARY ANSWER The 23rd ESHRE report highlights rising treatment cycles children born, alongside a decline twin deliveries owing decreasing multiple embryo transfers; fresh IVF or ICSI exhibited higher delivery rates, whereas frozen transfers (FET) showed pregnancy rates (PRs), decreased while maintaining...
Health policy-making require careful assessment of chronic kidney disease (CKD) epidemiology to develop efficient and cost-effective care strategies. The aim the present study was use RENALGO-EXPERT algorithm estimate global prevalence CKD in France. An expert group developed based on healthcare consumption. This has been applied French National claims database (SNDS), where no biological test findings are available a national for years 2018-2021. CONSTANCES cohort (+219 000 adults aged...
Abstract Background Very few previous studies have addressed the question of colorectal cancer (CRC) after childhood treatment. We aimed to quantify roles radiation therapy and chemotherapy agents in occurrence subsequent CRC. Methods A nested case–control study was conducted using 36 CRC cases 140 controls selected from 7032 five‐year survivors French Childhood Cancer Survivor Study (FCCSS) cohort, treated 1945 2000 France. The dose‐distribution metrics at site doses individual...
Background Since July 2018, numerous lots of valsartan have been found to be contaminated with N-nitrosodimethylamine (NDMA). We aimed assess the association between exposure products NDMA and risk cancer. Methods Results This study was based on data from Système National des Données de Santé, which is a national database that includes all French residents' health-related expenses. The target population consumers January 1, 2013 December 31, 2017, aged 40 80 years old. occurrence any...
Abstract Background: Unhealthy behaviors among childhood cancer survivors increase the risks for treatment adverse effects. We aimed to assess tobacco and cannabis use prevalence in this population identify factors associated with these consumptions. Methods: This study involved 2,887 5-year from French survivor (FCCSS) cohort. Data on health were compared those of controls general population. Associations current smoking clinical features, sociodemographic characteristics, health-related...
Health risk behaviors (HRB) of childhood cancer survivors (CCS) are generally studied separately, despite the evidence suggesting that HRB not independent. To our knowledge, few studies have examined profiles in former pediatric patients. In this study, we identified and predictors engaging unhealthy CCS. We used data from a French cohort CCS includes five-year diagnosed between 1945 2000 treated before reaching age 18, five centers France. A total 2961 adult answered self-reported...
Cancer survival is improving along with an increase in the potential for adverse kidney effects from antineoplastic treatments or nephrectomy. We sought to describe recent trends incidence of failure related and urinary tract cancers evaluate patient transplantation access.We used French Renal Epidemiology Information Network registry identify patients cancer 2003 2015. identified 287 1157 cases nephrotoxin- cancer-related failure, respectively. The main study outcomes were death...
En France, en 2021, 162 441 tentatives d'assistance médicale à la procréation (AMP) ont été réalisées. On observe une augmentation du nombre de femmes prises charges et d'enfants nés d'AMP. Le suivi long terme l'état santé ces populations représente un enjeu majeur publique. Système national des données français (SNDS) permet réaliser cette population. Notre objectif est décrire les cohorte FERTICOH. La inclut toutes âge procréer moins 46 ans entrant dans parcours d'AMP France ainsi que tous...
Le trastuzumab-emtansine (TDM-1) est le premier anticorps conjugué ciblant récepteur HER2 à avoir été développé. Ce traitement a offert de nouvelles alternatives thérapeutiques pour la prise en charge du cancer sein métastatique depuis 2013, et stade précoce 2019. L'objectif notre étude était caractériser les utilisateurs TDM-1 d'évaluer risque d'hospitalisation divers évènements indésirables. Nous avons identifié patients ayant eu au moins une délivrance entre janvier 2014 décembre 2022...
In women receiving chronic dialysis, fertility is impaired. The objectives of this study were to estimate the incidence rate pregnancies among childbearing age (15-50 years) dialysis from 2006 2020 in France, describe pregnancy outcomes and renal management during pregnancy.
Since 2020, trastuzumab deruxtecan (T-DXd) has been used in France for patients with previously treated HER2-positive or HER2-low metastatic breast cancer (mBC). We aimed to describe the real-world use of T-DXd and mBC, assess incidence selected adverse events leading hospitalizations among T-DX-d. Using French National Health Data System (SNDS), we identified having initiated mBC from September 30, 2020 2023. Patients were categorized three groups according BC subtype line treatment:...